Effects of risperidone on auditory event-related potentials in schizophrenia

被引:104
作者
Umbricht, D
Javitt, D
Novak, G
Bates, J
Pollack, S
Lieberman, J
Kane, J
机构
[1] Univ Zurich, Hosp Psychiat, Dept Res, CH-8029 Zurich, Switzerland
[2] Hillside Hosp, Dept Res, Glen Oaks, NY 11004 USA
[3] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10972 USA
[4] St Johns Univ, Dept Comp Informat & Decis Sci, Jamaica, NY 11439 USA
[5] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA
关键词
event-related potentials (ERPs); cognitive deficits; risperidone; atypical antipsychotics; schizophrenia; treatment;
D O I
10.1017/S1461145799001595
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Schizophrenia is associated with cognitive deficits for which treatments remain elusive. The effects of risperidone (an antipsychotic differing in some of its pharmacological properties from typical agents) on cognitive deficits have not been extensively investigated. Mismatch negativity (MMN), N2 and P3 are cognitive event-related potentials that index preattentive (MMN) and attention-dependent information processing (NZ, P3) and provide a measure of cognitive deficits in schizophrenia. The effects of risperidone treatment on MMN, N2 and P3 generation in chronic schizophrenic patients were investigated in an open-label uncontrolled study. Risperidone treatment significantly reduced psychotic symptoms. It was associated with a decrease of peak latencies, particularly pronounced for P3. However, it did not significantly affect abnormal MMN or P3 amplitudes. The results suggest an effect of risperidone on processing speed, particularly in attention-dependent tasks. These results are in agreement with findings in recent studies on the cognitive effects of risperidone.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 29 条
  • [1] *AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, V3
  • [2] CHANGES IN AUDITORY-P3 EVENT-RELATED POTENTIAL IN SCHIZOPHRENIA AND DEPRESSION
    BLACKWOOD, DHR
    WHALLEY, LJ
    CHRISTIE, JE
    BLACKBURN, IM
    STCLAIR, DM
    MCINNES, A
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1987, 150 : 154 - 160
  • [3] REACTION TIME AND PROGNOSIS IN ACUTE SCHIZOPHRENIA
    CANCRO, R
    SUTTON, S
    KERR, J
    SUGERMAN, AA
    [J]. JOURNAL OF NERVOUS AND MENTAL DISEASE, 1971, 153 (05) : 351 - &
  • [4] CATTS SV, 1995, AM J PSYCHIAT, V152, P213
  • [5] ERPS IN SCHIZOPHRENIA - EFFECTS OF ANTIPSYCHOTIC MEDICATION
    FORD, JM
    WHITE, PM
    CSERNANSKY, JG
    FAUSTMAN, WO
    ROTH, WT
    PFEFFERBAUM, A
    [J]. BIOLOGICAL PSYCHIATRY, 1994, 36 (03) : 153 - 170
  • [6] THE EFFECT OF CLOZAPINE ON COGNITION AND PSYCHIATRIC-SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
    GOLDBERG, TE
    GREENBERG, RD
    GRIFFIN, SJ
    GOLD, JM
    KLEINMAN, JE
    PICKAR, D
    SCHULZ, SC
    WEINBERGER, DR
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1993, 162 : 43 - 48
  • [7] Green MF, 1997, AM J PSYCHIAT, V154, P799
  • [8] Green MF, 1996, AM J PSYCHIAT, V153, P321
  • [9] IMPROVEMENT IN COGNITIVE FUNCTIONS AND PSYCHIATRIC-SYMPTOMS IN TREATMENT-REFRACTORY SCHIZOPHRENIC-PATIENTS RECEIVING CLOZAPINE
    HAGGER, C
    BUCKLEY, P
    KENNY, JT
    FRIEDMAN, L
    UBOGY, D
    MELTZER, HY
    [J]. BIOLOGICAL PSYCHIATRY, 1993, 34 (10) : 702 - 712
  • [10] The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients
    Hoff, AL
    Faustman, WO
    Wieneke, M
    Espinoza, S
    Costa, M
    Wolkowitz, O
    Csernansky, JG
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 15 (04) : 361 - 369